Clinical Trial Update: An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating daratumumab in adults with moderate to severe systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: UNKNOWN